Results 51 to 60 of about 25,624 (186)
Addiction, EarlyView.Abstract Background and aims Cocaine use disorder (CUD) is an increasingly widespread concern worldwide. Various pharmacological treatments have been investigated for CUD, but their efficacy remains unclear, and none have been licensed for treatment.
Craig Paterson +13 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
British Journal of Pharmacology, EarlyView.Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux +26 more
wiley +1 more source
Celecoxib inhibits osteoblast maturation by suppressing the expression of Wnt target genes
Journal of Pharmacological Sciences, 2017 Non-steroidal anti-inflammatory drugs (NSAIDs) have been shown to impair bone healing. We previously reported that in colon cancer cells, celecoxib, a COX-2-selective NSAID, inhibited the canonical Wnt/β-catenin signaling pathway. Since this pathway also
Akihiro Nagano +4 more
doaj +1 more source
Effect of Medication Intake on Dental Implant‐Related Outcomes—A Scoping Review
Clinical Oral Implants Research, EarlyView.ABSTRACT Objective The objective of this scoping review was to evaluate the effect of systemic medications on dental implant outcomes in medically compromised patients. Material and Methods Electronic and manual searches were conducted for this scoping review.
Alberto Monje +4 more
wiley +1 more source
Canadian Journal of Kidney Health and DiseaseBackground: Celecoxib is a COX-2 nonsteroidal anti-inflammatory drug (NSAID). It is widely used for the treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
Hesham A. M. I. Khalifa +2 more
doaj +1 more source
Cell Proliferation, EarlyView.Polyamine metabolism is innervation responsive and involved in denervation‐induced muscle atrophy. Inhibition of polyamine metabolism attenuates muscle atrophy by restraining proteolysis and preserving MuSCs homeostasis. Denervation‐induced activation of FAP‐derived FGF7 drives premature MuSCs activation, while DFMO suppresses this paracrine cue to ...
Mingming Zhang +9 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Background Pharmacogenomic‐guided medication management optimises drug therapy to enhance patient outcomes. Despite clinical utility, implementation in Australia remains limited, partly due to the lack of clear and consistent guidance. Aim This study evaluated the presence and consistency of pharmacogenomic testing indication categories and ...
Ruby Soueid +4 more
wiley +1 more source
Journal of Veterinary Pharmacology and Therapeutics, EarlyView.ABSTRACT Cyclooxygenases (COX‐1 and COX‐2) are key enzymes in the biosynthesis of prostanoids, which mediate physiological functions, inflammation, and the process of carcinogenesis. In dogs and cats, lower urinary tract diseases are prevalent and often complex, requiring targeted therapeutic interventions.
Reiner Silveira de Moraes +8 more
wiley +1 more source
Journal of Pain Research, 2018 Sooyoung Shin1,2 1Department of Clinical Pharmacy, College of Pharmacy, Ajou University, Yeongtong-gu, Suwon, Republic of Korea; 2Research Institute of Pharmaceutical Science and Technology (RIPST), Ajou University, Yeongtong-gu, Suwon, Republic of Korea
Shin S
doaj